Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction

Exclusion Criteria

• •Cardiogenic shock
• •Documented history of HF with previous HF admission
• •Current hospitalization for acute HF primarily triggered by pulmonary embolism, cerebrovascular accident, or acute myocardial infraction
• •Interventions in the past 30 days prior or planned during the study: Major cardiac surgery, or Transcatheter aortic valve implantation (TAVI), or percutaneous coronary intervention (PCI), or MitraClip; Implantation of cardiac resynchronization therapy device; Cardiac mechanical support implantation
• •Current or expected heart transplant, left ventricular assist device (LVAD), intraaortic balloon pumping (IABP), or patients with planned inotropic support in an outpatient setting
• •Haemodynamically severe uncorrected primary cardiac valvular disease planned for surgery or intervention during the course of the study
• •eGFR \<20 mL/min/1.73m2 as measured during index hospitalization (latest measurement before randomization) or patients requiring dialysis
• •Type 1 diabetes mellitus (DM)
• •History of ketoacidosis, including diabetic ketoacidosis
• •Current or prior treatment with SGLT2 inhibitors in the 90 days prior to enrolment.